title: [Hyponatremia and tolvaptan : what is the situation 5 years after approval?].
abstract: The diuretic tolvaptan has been approved for more than 5 years for the indications of euvolemic hyponatremia due to syndrome of inappropriate antidiuretic hormone (SIADH) secretion. In recent years many patients have been treated with tolvaptan and many physicians could gather practical experience. Other countries, such as the USA had already gained greater experience, also in the indications for hypervolemic hyponatremia. After approval was granted more than 5000 patients worldwide were included in the so-called hyponatremia register and 22 active centers in Germany with 317 patients participated. Although some details from this now concluded register have been published, the final publication of the multinational post-authorization safety study on tolvaptan in the treatment of SIADH has not yet been published. In the years 2012 and 2013 two warning letters were issued on tolvaptan. The first letter warned of the risk of a faster increase in serum sodium using tolvaptan and provided detailed information on how the risk of osmotic demeyelination can be minimized. So far only one proven case of osmotic demelination syndrome (ODS) is known; however, this occurred following incorrect use of tolvaptan in a monotherapy. The second warning letter provided information on the potential risk (reversible) of liver damage by tolvaptan, which resulted from the TEMPO 3:4 study. In this study tolvaptan was used in a higher dosage for therapy of autosomal dominant polycystic kidney disease. Although the European renal best practice (ERBP) guidelines from 2014 did not recommend tolvaptan for the indications of SIADH, other guidelines came to different conclusions. In summary, 5 years after the approval of tolvaptan there is still no consensus. At the current time many questions still remain unanswered. Initiation of therapy with tolvaptan remains reserved for experienced physicians in hospitals. Treatment must be adapted on the basis of a clinical estimation of the individual situation of each patient.
authors.affiliation: KRH Klinikum Nordstadt, KRH Klinikum Region Hannover, Haltenhoffstr. 41, 30167, Hannover, Deutschland, johannes.hensen@krh.eu.
authors.forename: J
authors.initials: J
authors.lastname: Hensen
mesh_terms: D001552:Benzazepines / Q000008:administration & dosage* / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000517:prevention & control; D004232:Diuretics / Q000008:administration & dosage / Q000009:adverse effects; D017277:Drug Approval; D019317:Evidence-Based Medicine; D005858:Germany; D006955:Hypernatremia / Q000139:chemically induced* / Q000517:prevention & control; D007010:Hyponatremia / Q000150:complications* / Q000188:drug therapy*; D018570:Risk Assessment; D000077602:Tolvaptan; D016896:Treatment Outcome
chemical_list: D001552:Benzazepines; D004232:Diuretics; D000077602:Tolvaptan